Japan DNA Vaccine Market to Reach $32.2 Million by 2035

The Japan DNA vaccine market was valued at $21.7 million in 2025 and is projected to reach $32.2 million by 2035, expanding at a CAGR of 4.1% during the forecast period from 2026 to 2035. The market is experiencing measurable growth driven by the increasing number and advancement of DNA vaccine clinical programs, particularly for infectious disease targets such as COVID-19. Key Japanese biotech firms, including AnGes Inc., have progressed plasmid DNA vaccine candidates (AG0302-COVID19) into Phase II/III trials, demonstrating sustained clinical investment and scientific validation of DNA-based platforms in the country. Clinical trial activity reflects broader confidence in plasmid DNA vaccine technology as a viable modality for human use in Japan’s regulated environment, which in turn attracts further stakeholder participation from academia and industry. This expanding pipeline is fostering infrastructure investments in manufacturing and delivery technologies that support downstream development and future commercialization. As such, the growing volume of advanced clinical programs is strengthening the overall market environment for DNA vaccines in Japan.

Browse the full report description of “Japan DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/japan-dna-vaccines-market

Key Findings on Clinical Activity in Japan’s DNA Vaccine Segment

• AG0302-COVID19, a plasmid DNA vaccine candidate developed by AnGes Inc., is in a Phase II/III clinical study in healthy adult volunteers, indicating progression beyond early safety evaluation.
• Clinical trial registrations show that multiple AG0302-COVID19 studies are actively listed, reflecting sustained research momentum in DNA vaccine clinical development.
• Phase I/II assessments of intradermal and intramuscular administration methods have been documented with measurable immune responses and acceptable safety profiles, highlighting flexible delivery pathways.
• DNA vaccine candidates in Japan are part of broader infectious disease development strategies, aligning with regulatory readiness to support novel biologics within the country.
• Progression into later-stage trials suggests increasing confidence among developers and investors in the clinical viability of DNA vaccines relative to other platforms.
• Japanese clinical activity is contributing to the globalization of DNA vaccine research, with multiple collaborative and multi-site protocols documented through international registries.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • Technology
  • Application
• Competitive Landscape – AGC Biologics, AnGes Inc., Kaneka Corp., Takara Bio Inc., Takeda Pharmaceutical Company Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Japan DNA Vaccine Market Report Segment

By Type

• Animal DNA Vaccine
• Human DNA Vaccine

By Technology

• Plasmid DNA Vaccines Technology
• Plasmid DNA Delivery Technology

By Application

• Oncology
• Infectious Diseases
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-dna-vaccines-market